Respira Labs, a leading respiratory healthcare tech company, has recently announced an AI-powered wearable lung monitor. The wearable could help with early diagnosis and management of chronic obstructive pulmonary disease (COPD), asthma, and COVID-19.
The chest wearable Sylvee 1.0 is a complete, clinical-grade respiratory health wearable providing 2 weeks’ non-stop monitoring.
“Well-established science shows that air trapping can be measured with more than 90% accuracy using low-frequency sound. There is a clear difference in the acoustic resonance spectra of COPD patients versus healthy controls,” explained Dr. Maria Artunduaga, Respira Lab’s founder and CEO. “With more than 100 million Americans affected by COPD, COVID-19 and asthma, and with an aging population, it can be lifesaving to remotely and accurately monitor lung function and discover a problem early enough to avoid serious consequences. Our goal is to flag abnormalities early, enable earlier treatment at home and empower patients to manage their own health.”
Sylvee monitors your pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, temperature around the clock for 2-weeks to deliver actionable insights on how you can optimize your day-to-day respiratory health.
Since the pandemic, respiratory diseases have become the #1 cause of death in the U.S. and expenses.
It’s estimated that 10% of the world’s population will be affected with a chronic respiratory disease by 2030.
The standard of care today relies on heavily biased questionnaires and inaccurate pulse-oximeters, missing 50% of respiratory exacerbations leading to very expensive hospitalizations ($19,000 to $50,000) and early deaths (one out of two COPDers hospitalized today will die within the next two years), according to Repira Labs.
Respira’s ground-breaking wearable patch uses audible sound to accurately measure trapped air.
Sylvee is named after Artunduaga’s grandmother, who suffered from COPD and died after symptoms quickly worsened without detection.